Intelligent Bio Solutions Inc. provided unaudited preliminary earnings guidance for the second quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -2.07% |
|
-8.25% | -53.39% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.39% | 5.67M | |
-39.38% | 8.28B | |
+9.28% | 3.62B | |
-1.48% | 2.24B | |
-22.85% | 1.94B | |
-18.07% | 1.72B | |
+10.53% | 962M | |
+17.17% | 734M | |
-9.17% | 690M | |
-33.88% | 477M |
- Stock Market
- Equities
- INBS Stock
- News Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023